ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ABL tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)1–3.